Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Combines formulation development, clinical pharmacology, and manufacturing, including selection of solubility enhancement technologies, pediatric palatability improvement, and formulation development for multiple administration routes.
Provides PBPK, IVIVC and formulation/clinical-design modeling, available standalone or integrated with its clinical studies.
Program / service
Target / indication
Representative stage
Evidence & scope
Formulation development / contract manufacturing capabilities
Defined by the client project · Defined by the client project
Services / platform
Service pages do not establish human evidence for every project
PBPK modeling
Supports first-in-human predictions and special-population scenarios; predictions are not clinical findings · Not applicable; population depends on protocol
Services / platform
Clinical research service, not the company’s therapeutic product
IVIVC / formulation modeling
Numerical or mechanistic IVIVC supporting formulation and CMC-change assessment · Not applicable; population depends on protocol
Services / platform
Clinical research service, not the company’s therapeutic product
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.
European Journal of Drug Metabolism and Pharmacokinetics
A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.
A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Available capacity, site-specific qualifications, project delivery history, pricing, and technology transfer terms require confirmation with the execution entity.
Company service pages support the stated scope but do not establish clinical validation of every dosage form or client program.
Website capabilities are not completed vendor qualification; scope, executing site and current credentials require confirmation.
